The role of nicotine content information in smokers' subjective responses to nicotine and placebo inhalers

Darredeau, Christine; Barrett, Sean P.

doi:10.1002/hup.1159

Cited by 21 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, expectancies about medication effects, rather than actual pharmacologic effect, seem to be a key mechanism in nicotine withdrawal relief in this sample. This has also been shown in previous studies, where expectations about receiving active nicotine rather than placebo was associated with less withdrawal symptoms, greater adherence to cessation treatment (Dar et al 2005;Darredeau and Barrett 2011;Ben Taleb et al 2015).…”

Section: Nicotine Refsupporting

confidence: 73%

Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting

Taleb

Ward

Asfar

et al. 2016

Int J Public Health

View full text Add to dashboard Cite

show abstract

Section: Nicotine Refsupporting

confidence: 73%

Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting

Taleb

Ward

Asfar

et al. 2016

Int J Public Health

View full text Add to dashboard Cite

show abstract

“…However, average heart rate was elevated following nicotine lozenge administration, regardless of expectancy, indicating that the dose of nicotine was sufficient to produce at least some pharmacological effect. Additionally, previous balancedplacebo research using nicotine and placebo gum and inhalers have also failed to find an effect of nicotine pharmacology on measures of tobacco-related craving (Darredeau and Barrett, 2010;Gottlieb et al, 1987;Hughes, 1989). Continued balancedplacebo research using a variety of NRTs and dose ranges will be important in establishing a more comprehensive understanding of the relative impact of nicotine pharmacology and expectancy on withdrawal symptoms and cigarette craving more broadly.…”

Section: Discussionmentioning

confidence: 99%

The impact of nicotine lozenges and stimulus expectancies on cigarette craving

2014

View full text Add to dashboard Cite

Reduced craving associated with nicotine replacement therapy use is frequently attributed to the effects of nicotine pharmacology, however non-pharmacological factors may also play a role. This study examined the impact of nicotine pharmacology and non-pharmacological components of an acute nicotine lozenge (4 mg) on cigarette craving, mood and heart rate in 70 daily smokers (36 male). Smoking-related stimuli were used to assess cue-induced craving. Participants were randomly assigned to one of four conditions in a balanced placebo design where half the participants were provided deceptive information regarding the nicotine content of a lozenge. Subjective ratings of craving and mood were collected and heart rate was assessed before and after neutral and smoking cues. Nicotine expectancy reduced withdrawal-related craving (p = 0.006) regardless of actual nicotine administration while combined nicotine expectancy and administration reduced intentions to smoke (p = 0.046) relative to each of the other conditions. Exposure to smoking-related stimuli increased cigarette craving (p ≤ 0.001) and negative affect (p ≤ 0.001) regardless of expectancy or pharmacology. Following the smoking cue, women reported a greater increase in withdrawal-related craving than men (p = 0.027). Findings suggest that both pharmacological and non-pharmacological components of nicotine lozenge administration contribute to its acute effects on craving, yet neither appears effective in preventing craving triggered by exposure to environmental smoking stimuli.

show abstract

“…Beliefs and expectations about nicotine patch's effectiveness has been shown to affect adherence beyond whether an active nicotine or a placebo patch is received (Darredeau and Barrett, 2010). In our study, adherence to pharmacologic and behavioral treatment was greater among those who believed that they had received nicotine compared with those who believed they had received placebo, regardless of the actual patch assignment.…”

Section: Discussionmentioning

confidence: 99%

Predictors of adherence to pharmacological and behavioral treatment in a cessation trial among smokers in Aleppo, Syria

Taleb

Ward

Asfar

et al. 2015

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Introduction The development of evidence-based smoking cessation programs is in its infancy in developing countries, which continue to bear the main brunt of the tobacco epidemic. Adherence to treatment recommendations is an important determinant of the success of smoking cessation programs, but little is known about factors influencing adherence to either pharmacological or behavioral treatment in developing countries settings. Our study represents the first attempt to examine the predictors of adherence to cessation treatment in a low-income developing country. Methods Predictors of adherence to pharmacological and behavioral treatment were identified by analyzing data from a multi-site, two-group, parallel-arm, double-blind, randomized, placebo-controlled smoking cessation trial in primary care clinics in Aleppo, Syria. Participants received 3 in-person behavioral counseling sessions plus 5 brief follow-up phone counseling sessions, and were randomized to either 6 weeks of nicotine or placebo patch. Results Of the 269 participants, 68% adhered to pharmacological treatment, while 70% adhered to behavioral counseling. In logistic regression modeling, lower adherence to pharmacological and behavioral treatment was associated with higher daily smoking at baseline, greater withdrawal symptoms, and perception of receiving placebo instead of active nicotine patch. Women showed lower adherence than men to behavioral treatment, while being assigned to placebo condition and baseline waterpipe use were associated with lower adherence to pharmacological treatment. Conclusion Adherence to cessation treatment for cigarette smokers in low-income countries such as Syria may benefit from integrated cessation components that provide intensive treatment for subjects with higher nicotine dependence, and address concurrent waterpipe use at all stages.

show abstract

The role of nicotine content information in smokers' subjective responses to nicotine and placebo inhalers

Abstract: Findings suggest that psychological factors play an important role in smokers' subjective responses to nicotine inhalers, the effects of which cannot be solely attributed to the direct pharmacological effects of nicotine.

Cited by 21 publications

References 17 publications

Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting

Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting

The impact of nicotine lozenges and stimulus expectancies on cigarette craving

Predictors of adherence to pharmacological and behavioral treatment in a cessation trial among smokers in Aleppo, Syria

Contact Info

Product

Resources

About